Versant Ventures

Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies, with a primary emphasis on biotechnology companies discovering and developing novel therapeutics. With $5.5 billion under management and offices across the US, Canada, and Europe, the firm combines deep investment, operating, and R&D expertise to take a hands-on approach to company building — including through its proprietary Discovery Engines, in-house laboratory facilities staffed by multi-disciplinary scientists who actively co-found and launch novel biotechnology companies alongside academic researchers. Versant's core strategy centers on partnering with academic founders and experienced biotech teams to transform scientific discoveries into commercial enterprises, with a particular focus on platform companies in gene therapy, gene editing, cell therapy, precision oncology, and novel small molecule constructs. The firm builds approximately two-thirds to three-quarters of its portfolio companies from scratch, while selectively joining syndicates for exceptional Series A opportunities. As Brad Bolzon has stated, 'These innovations — advances in engineering new cell and gene therapies, developing the next generation of antibodies and therapeutic proteins, and conceiving novel small molecule constructs — are at the heart of our investment model.'